Clinical Trial Update: Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating pressure-enabled delivery of SD-101 in combination with checkpoint blockade for primary liver tumors has been terminated. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Pressure Enabled Delivery of SD-101 With Checkpoint Blockade (SD-101)

Snippet

Sponsor: TriSalus Life Sciences, Inc. | Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 1, Phase 2 | Status: TERMINATED